CAYA Cancer Retrospective Cohort Study

Sponsor
Resonance, Inc.
Study ID
NCT07246213
Status
Recruiting
Apply to this trial

Conditions

  • Acute Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia (ALL)
  • Adolescent Cancer
  • Childhood Cancers
  • Lymphoblastic Lymphoma
  • Lymphoblastic Lymphoma (LBL)
  • Young Adult Cancer

Eligibility Criteria

Sex
ALL
Age
0 Years - 21 Years
Healthy Volunteers
Not accepted

Interventions

  • Retrospective Medical Record Review — OTHER
    This study involves retrospective review of medical records of pediatric, adolescent, and young adult cancer patients (ages 0-21 years) treated at participating oncology centers in Guatemala, Honduras, El Salvador, Armenia, and Tanzania. No experimental drug, device, or behavioral intervention is being administered. Data abstraction will be performed to assess treatment failure, therapy-related toxicities, and clinical outcomes.

Study Details

Despite advances in cancer treatment, significant disparities in outcomes persist between high-income countries (HICs) and low-and middle-income countries (LMICs). Around 80% of children with cancer live in LMICs, where they face challenges such as delayed diagnosis, misdiagnosis, comorbidities, distance to treatment, financial barriers, and limited access to risk-adapted therapies. Acute lymphoblastic leukemia(ALL)/lymphoblastic lymphoma(LBL), for example, is one of the greatest success stories in pediatric oncology, however, such improvements are not evenly distributed worldwide, and the outcomes for leukemia patients are poorer in LMICs compared to HICs, primarily due to reduced access to quality healthcare. This study aims to assess cancer treatment outcomes in LMICs, focusing on acute lymphoblastic leukemia/lymphoblastic lymphoma. The findings will inform future studies to implement evidence-based interventions that improve care quality and reduce treatment failures through targeted strategies.

Key Dates

First listed
Nov 24, 2025
Start date
Jun 4, 2025
Status verified
Aug 2025
Primary completion
Jun 4, 2028
Completion
Dec 4, 2028

Study Design

Enrollment
18,000 participants (estimated)

Arms

  • Arm: All Cancer Diagnoses
    Patients aged 0-21 years with any type of cancer diagnosis. Retrospective medical record review will capture incidence of treatment failure, including relapse, progression, or abandonment.
  • Arm: Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma
    Patients aged 0-21 years diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma. Retrospective review will focus on therapy-related toxicities and treatment outcomes in this subgroup.

Primary Outcome Measure

To estimate the incidence of treatment failure, in patients with any type of cancer diagnosis. [ Time Frame: 3 years from date of cancer diagnosis (retrospective follow-up via medical records; patients without an event will be censored at last contact within 3 years) ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies